IBK Corporate Bank Opposes KT&G Executive Appointments

News by 2FIRSTS.ai
Mar.13.2024
IBK Corporate Bank Opposes KT&G Executive Appointments
IBK Corporate Bank opposes nominations of KT&G executives, calling for better corporate governance structure with independent directors.

According to South Korean media outlet Naver, IBK Corporate Bank officially announced its opposition to the appointment of Bang Kyung-man and others recommended by the KT&G board as directors.

 

The industrial bank emphasized that as the largest shareholder of KT&G, they have put forth a shareholder proposal opposing such nominations, and are urging other shareholders to join their stance.

 

Finance industry professionals say that industrial banks hope to improve the governance structure of companies by enhancing the professionalism and independence of the board of directors. They are urging other shareholders to oppose the appointment of Bang Kyung-man and Lin Minkui, while supporting the candidate recommended by the industrial bank, Choi Dong-hwan. It is understood that these measures may be aimed at preventing Bang Kyung-man from being appointed as the representative of KT&G at the upcoming shareholders' meeting.

 

With the appointment of Bang Kyung-man, KT&G's operating profit has decreased by 20%, and issues such as overseas business trips have become a focus for the company. IBK Industrial Bank has expressed strong dissatisfaction with this and stated that KT&G's external directors were reappointed without adequately addressing market concerns, increasing the power of external directors and creating a clear conflict with the goal of increasing industrial value.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria has released its full-year 2025 results, reporting full-year net revenues of $23.279 billion, down 3.1% year over year. Domestic cigarette shipment volume fell 10% for the year. on! nicotine pouches reached a 7.7% share of the U.S. oral tobacco category in the fourth quarter. NJOY posted $21 million in net revenues in Q4, while full-year net revenues were negative $13 million (mainly due to returns and related factors).
Jan.30 by 2FIRSTS.ai
Cyprus customs seizes 269 packs containing cannabis and THC; Pharmacy Department flags unauthorized CBD products
Cyprus customs seizes 269 packs containing cannabis and THC; Pharmacy Department flags unauthorized CBD products
The report says an international operation across EU countries aimed at detecting illicit substances in e-cigarettes also took place in South Cyprus, where multiple e-liquid items and products containing cannabis and THC were seized. It states the operation, titled “eVAPER8,” was conducted by the International Narcotics Control Board (INCB) in November and December to identify e-cigarette liquids that may contain synthetic drugs.
Feb.09 by 2FIRSTS.ai
2Firsts’ Nine Global Turning Points: How 2025 Reshaped the Nicotine Industry
2Firsts’ Nine Global Turning Points: How 2025 Reshaped the Nicotine Industry
In 2025, the global nicotine industry reached a critical turning point. Regulatory realignment, category shifts, capital repositioning and technological intervention unfolded in parallel, loosening old structures while new ones took shape. 2Firsts reviews nine pivotal events that reshaped the industry’s trajectory.
Jan.14
Belgium: BAT plans to cut 51 jobs at Groot-Bijgaarden site
Belgium: BAT plans to cut 51 jobs at Groot-Bijgaarden site
British American Tobacco (BAT) has announced plans to cut 51 jobs at its Groot-Bijgaarden facility in Belgium, disclosed during a special works council meeting.
Jan.15 by 2FIRSTS.ai
U.S. FDA Posts Final ZYN MRTP Materials, Sets March 4 Deadline for Public Comments
U.S. FDA Posts Final ZYN MRTP Materials, Sets March 4 Deadline for Public Comments
U.S. FDA has released the final batch of materials for ZYN MRTP applications and set March 4 (11:59 p.m. ET) as the deadline for public comments to be considered in the agency’s review.
Feb.03 by 2FIRSTS.ai
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai